slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 1,321-1,350
Pages 1,437
Rows per page 30
Arc
1,321-1,350 of 43,093
16
The slide includes a list of bullet points explaining the rationale behind the observed trends in capital ratios.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
17
The chart is a 3D pie chart representing loan distribution.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
18
Data as of September 30, 2022.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
19
The chart illustrates the bridge between the Q2 2022 ending balance and the Q3 2022 ending balance, accounting for net charge-offs, individual analysis, and growth/qualitative factors.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
20
The chart highlights the drivers of expense growth, specifically talent and technology investments.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
21
The slide tracks deposit growth and cost trends from Q3 2021 to Q3 2022.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
22
Includes a pie chart for portfolio breakout and a bar chart for yield/spread trends.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
23
Includes footnotes regarding non-GAAP measures and CECL implementation.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
24
Includes footnotes explaining non-GAAP measures and tax-equivalent calculations.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In2 hits
09
The slide uses a hub-and-spoke diagram to illustrate the three core pillars of the platform.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
14
Hilltop Holdings | Results Presentation Deck | 19 slidesHilltop Holdings | Results Presentation Deck | 19 slides · Hilltop Holdings
Conference presentation Investor relations Beat · FinancialsLoop · Logic Chain2 hits
09
The slide uses three distinct chart types to convey market stability, resilience, and growth drivers.Lanvin | Investor Presentation Deck | 58 slides · Lanvin Group
Pitch deck Investor relations Beat · Problem2 hits
10
The slide uses a geographic grouping to highlight Lanvin Group's unique positioning in Asia compared to Western-centric competitors.Lanvin | Investor Presentation Deck | 58 slides · Lanvin Group
Pitch deck Investor relations Beat · Problem2 hits
09
Includes definitions of acronyms and citations for preclinical studies.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
10
Study methodology involves 10-week treatment on high fat/fructose/CHO diet.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
11
Study design timeline included; statistical significance noted for treatment groups.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
12
Includes definitions for abbreviations and source citations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
13
NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
14
Company branding slide for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
15
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
16
Data from preclinical study in HF-DIO mice.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
17
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
18
Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
19
Includes study methodology timeline and statistical significance markers.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
20
NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
22
Includes a bar chart for NASH diagnosis and a funnel diagram for Obesity patient progression.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
07
The slide uses a four-column layout to describe the biological composition of each product.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Beat · Solution2 hits
13
The slide uses a background map of the world to emphasize the global nature of the condition, despite the specific US prevalence statistic.PaxMedica | Investor Presentation Deck | 24 slides · PaxMedica
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
14
The slide uses a biological process diagram to explain the drug's mechanism.PaxMedica | Investor Presentation Deck | 24 slides · PaxMedica
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
15
Includes a medical illustration of the intranasal drug delivery pathway to the brain.PaxMedica | Investor Presentation Deck | 24 slides · PaxMedica
Pitch deck Investor relations Beat · Solution2 hits